Navigation Links
Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy)
Date:7/16/2014

REDWOOD CITY, Calif., July 16, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. announced the start of its Phase 3 trial of CHS-0214, a proposed biosimilar of etanercept  (Enbrel®), in chronic plaque psoriasis (the RaPsOdy trial).  This announcement follows the recent initiation of a Phase 3 trial of CHS-0214 in rheumatoid arthritis.  The Phase 3 psoriasis trial is a 48-week, randomized, double-blind, active-control, parallel-group, multicenter, global study in subjects with active, chronic plaque psoriasis who are naïve to systemic biologic therapy.  The study will seek to demonstrate biosimilarity between CHS-0214 and Enbrel® in terms of efficacy, safety and immunogenicity.  The primary efficacy endpoint is based on percent improvement in the Psoriasis Area and Severity Index (PASI) at 12 weeks.

"The initiation of the Phase 3 RaPsOdy trial is an important step toward our goal of increasing access to biosimilar etanercept for patients worldwide," said Barbara Finck, M.D., Chief Medical Officer of Coherus.  "It represents a pivotal study in the global clinical development for CHS-0214 and, if positive, will provide support for our marketing applications in Europe, the United States, and a number of other countries."

"Based on our evaluation of the analytical, nonclinical and clinical pharmacokinetic similarity of this molecule, we believe that this molecule has met our rigorous internal criteria for initiating our second Phase 3 trial in 2014," said Denny Lanfear, Coherus Chief Executive Officer.  "In concert with our partner Baxter, we are pleased to advance this product into late-stage development."

"With two late-stage trials now underway in partnership with Coherus, we are advancing our col
'/>"/>

SOURCE Coherus BioSciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
2. Coherus anuncia que CHS-0214 (biosimilar etanercept propuesto) supera punto final primario en decisivo estudio clínico farmacocinético
3. Coherus Biosciences als Präsentator zur J.P. Morgan Annual Healthcare Conference 2014 eingeladen
4. Coherus Biosciences Invited to Present at 2014 J.P. Morgan Annual Healthcare Conference
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 27, 2015 /CNW/ - Export Development Canada (EDC) today announced ... Montreal,s Valeant Pharmaceuticals International, Inc. ... company. The loan is part of ... Valeant is using to fund the repayment of certain ... gastrointestinal pharmaceutical company based in the US. Salix was ...
(Date:5/26/2015)... , May 26, 2015  The National Association ... is pleased to announce that general availability for the ... all pharmacies and pharmacy-related entities may apply for .pharmacy ... was launched in 2014, and NABP has approved more ... during prior limited registration periods. NABP created the .pharmacy ...
(Date:5/26/2015)... , May 26, 2015  AbbVie (NYSE: ... Phase 3 GIFT-I study of its investigational, all-oral, ... treatment with ombitasvir/paritaprevir/ritonavir at the Annual Meeting of ... Japan . 1 GIFT-I evaluated ... infected Japanese patients, with and without cirrhosis, who ...
Breaking Medicine Technology:EDC provides Valeant Pharmaceuticals with USD 67.5 M to support recent Salix Pharmaceuticals acquisition 2General Availability for .Pharmacy Domain Names Begins June 3, 2015 2AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 2AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 3AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 4AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 5AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 6
... WHO: , International SOS, the world,s leading ... pandemic information and planning services to more than 350 leading ... MD - disease outbreak and pandemic specialist Moderator: Tim ... WHAT: , A Webinar, open to the public and ...
... NUREMBERG, Germany, October 13 The German medical ... C-arms Business,Development Strategy Leadership Award" from the independent market ... growth strategy,of the technology leader in the area of ... of important new markets, as well as the,securing of ...
Cached Medicine Technology:With Flu Season Underway, International SOS to Host H1N1 Update Webinar 2With Flu Season Underway, International SOS to Host H1N1 Update Webinar 3With Flu Season Underway, International SOS to Host H1N1 Update Webinar 4Award-Winning Medical Technology From Germany 2Award-Winning Medical Technology From Germany 3
(Date:5/26/2015)... Liverpool, Ohio (PRWEB) May 26, 2015 Mr. ... role since 2010, will start working together this week to ... an accomplished career in healthcare executive leadership and strategy. ... CEO prior to the hiring of Mr. Cochran. The Board ... skills will complement the improvement strategies implemented over the past ...
(Date:5/26/2015)... Beloved local Arizona company, Parker and Sons, ... drain clog guarantee or else its free. , Parker ... found here . What’s more, Parker and Sons offers ... in the company’s rich legacy, and immense success. , ... drain clog imaginable. Whether it be low water flow or ...
(Date:5/26/2015)... 2015 Over 700 doctors, nutritionists, nurses, ... to the secretaries of the U.S. Department of Agriculture ... urging them to embrace the 2015 Dietary Guidelines Advisory ... for human health, economic prosperity, and our nation’s food ... the letter, including: Dr. David Katz, founding director of ...
(Date:5/26/2015)... Now offering innovative, safe, and effective ... Dr. Hedi Belajouza in Tunisia extends the ... to the last detail — meticulous hair placement, artistic ... the harvested follicle — are all results in exceptionally ... in the artistry and talent of Tunisian hair transplant ...
(Date:5/26/2015)... VA (PRWEB) May 26, 2015 The ... experts at America’s 55 poison centers applaud the efforts ... of opioid addiction, according to Stephen T. Kaminski, JD, ... Prescribing of Controlled Substances Act, introduced by Senator Edward ... require prescribers of opioid pain medications and other controlled ...
Breaking Medicine News(10 mins):Health News:Parker and Sons Offers Special, Sixty Minute Drain Clean Guarantee or Else It’s on Them 2Health News:700 Doctors, Health Professionals, Including the American College of Lifestyle Medicine, Support Dietary Guidelines Message to Eat Less Meat, More Plants 2Health News:700 Doctors, Health Professionals, Including the American College of Lifestyle Medicine, Support Dietary Guidelines Message to Eat Less Meat, More Plants 3Health News:Hair Transplant Center in Tunisia Now Offering Innovative Restoration Technology 2Health News:Hair Transplant Center in Tunisia Now Offering Innovative Restoration Technology 3Health News:Hair Transplant Center in Tunisia Now Offering Innovative Restoration Technology 4Health News:American Association of Poison Control Centers Supports Legislative Initiatives Targeting the Responsible Prescription of Opioid Pain Medication 2Health News:American Association of Poison Control Centers Supports Legislative Initiatives Targeting the Responsible Prescription of Opioid Pain Medication 3
... research links ,silent strokes, or small spots of dead brain cells, ... loss in the elderly. The study is published in the January ... of the American Academy of Neurology. "The new aspect ... it examines silent strokes and hippocampal shrinkage simultaneously," said study author ...
... Dennis Thompson HealthDay Reporter , WEDNESDAY, Dec. 28 ... but old-fashioned letter-writing may have a more beneficial lasting effect ... war zones, most in Iraq, researchers found that letters from ... onto paper or typed into an email -- served as ...
... Thompson HealthDay Reporter , WEDNESDAY, Dec. 28 (HealthDay ... old-fashioned letter-writing may have a more beneficial lasting effect on ... zones, most in Iraq, researchers found that letters from home ... paper or typed into an e-mail -- served as an ...
... , WEDNESDAY, Dec. 28 (HealthDay News) -- Regular beer and ... of gluten and could cause problems for people with celiac ... barely, which contains a form of gluten called hordein. However, ... or reduces it to very low levels, according to a ...
... Southwestern Medical Center study using a sophisticated "glass mouse" research ... caused in patients by speedy drug metabolism rather than inconsistent ... in The Journal of Infectious Diseases is borne ... to treat one of the world,s major infectious diseases. Health ...
... Reporter , TUESDAY, Dec. 27 (HealthDay News) -- A new test ... whether someone is really having a heart attack earlier than is ... into the bloodstream when the heart muscle has been damaged such ... the heart, the more troponin there will be in the blood. ...
Cached Medicine News:Health News:In High-Tech Age, the Good Old Letter Still Holds Sway 2Health News:In High-Tech Age, the Good Old Letter Still Holds Sway 3Health News:In the Age of Email, the Good, Old Letter Still Holds Sway 2Health News:In the Age of Email, the Good, Old Letter Still Holds Sway 3Health News:UT Southwestern research suggests new way to ensure effectiveness of TB treatment 2Health News:New Blood Test May Rule Out Heart Attacks More Quickly 2
... are diagnosed with varicose veins every year, ... seek treament and are apprehensive of conventional ... an effective alternative to conventional therapies., Traditional ... phlebectomy), is considered a laborious procedure by ...
...
Inquire...
... Innovative Image Quality in a Compact Size ... higher end systems along with Alokas latest ... superb images., Traditionally, portable units suffer from ... quality. Alokas SSD-900 sets new standards for ...
Medicine Products: